Quantifying Plasmodium vivax radical cure efficacy: a modelling study integrating clinical trial data and transmission dynamics - 22/05/25
Summary |
Background |
Plasmodium vivax forms dormant liver stages (hypnozoites) that can reactivate weeks to months after primary infection. Radical cure requires a combination of antimalarial drugs to kill both the blood-stage and liver-stage parasites. Hypnozoiticidal efficacy of the liver-stage drugs primaquine and tafenoquine cannot be estimated directly because hypnozoites are undetectable. We aimed to estimate hypnozoiticidal efficacy from clinical trial data, and quantify the community-level impact of implementing case management with radical cure.
Methods |
We calibrated a novel P vivax Recurrence Model to publicly available data from prospective clinical trials to estimate the hypnozoiticidal efficacy of different supervised primaquine (3·5 mg/kg or 7 mg/kg over 7 or 14 days) and tafenoquine (5 mg/kg or 7·5 mg/kg single dose) regimens in patients with normal glucose-6-phosphate dehydrogenase (G6PD) activity. We used an existing P vivax Individual-Based Model to quantify the 5-year impact of case management with unsupervised primaquine or tafenoquine regimens across various transmission settings.
Findings |
We estimated median hypnozoiticidal efficacies of 99·1% (95% credible interval 96·0–100) for primaquine 7 mg/kg over 14 days; 96·3% (90·8–99·7) for primaquine 7 mg/kg over 7 days; 72·3% (68·1–76·3) for primaquine 3·5 mg/kg over 7 or 14 days; 62·4% (49·1–76·3) for tafenoquine 5 mg/kg single dose; and 87·5% (62·1–99·3) for tafenoquine 7·5 mg/kg single dose. 5 years of community-level tafenoquine case management was estimated to reduce P vivax transmission by 74–79% where pre-intervention prevalence as measured by PCR was low (<2%) and by 17–20% where prevalence as measured by PCR was high (around 35%). Similar 5-year reductions were estimated with primaquine case management only when adherence to the primaquine regimen was above 50%.
Interpretation |
Substantial reductions in prevalence as measured by PCR were predicted with primaquine and tafenoquine regimens if these could be implemented with high coverage and adherence. The benefits of preventing P vivax relapses need to be balanced against the risks of inducing severe haemolysis in patients with G6PD deficiency.
Funding |
Bill & Melinda Gates Foundation and Horizon Europe.
Le texte complet de cet article est disponible en PDF.Plan
Vol 25 - N° 6
P. 668-677 - juin 2025 Retour au numéro
Article précédent
- Effect of mass drug administration on malaria incidence in southeast Senegal during 2020–22: a two-arm, open-label, cluster-randomised controlled trial
- El-hadji Konko Ciré Ba, Michelle E Roh, Abdoulaye Diallo, Tidiane Gadiaga, Amadou Seck, Sylla Thiam, Ari Fogelson, Seynabou Gaye, Ibrahima Diallo, Aminata Colle Lo, Elhadji Diouf, Oumar Gallo Ba, Alioune Badara Gueye, Xue Wu, Paul Milligan, Tabitha Kibuka, Moustapha Hama, Erin Eckert, Julie Thwing, Adam Bennett, Roly Gosling, Jimee Hwang, Doudou Sene, Fatou Ba, Bayal Cissé, Katharine Sturm-Ramirez, Michelle S Hsiang, Jean Louis Ndiaye
- Multi-antigen serology and a diagnostic algorithm for the detection of arbovirus infections as novel tools for arbovirus preparedness in southeast Europe (MERMAIDS-ARBO): a prospective observational study
- Louella M R Kasbergen, Erwin de Bruin, Felicity Chandler, Louise Sigfrid, Xin Hui S Chan, Lauren Hookham, Jia Wei, Siyu Chen, Corine H GeurtsvanKessel, Sandra Scherbeijn, Remi N Charrel, Nazli Ayhan, James L Lee, Victor M Corman, Chantal Reusken, Katherine Loens, Corneliu Petru Popescu, Mihaela Lupse, Violeta Briciu, Anca Meda Văsieşiu, Pellumb Pipero, Arjan Harxhi, Edmond Puca, Albina Ponosheci Biçaku, Maja Travar, Maja Ostojić, Rusmir Baljic, Jurica Arapović, Dragan Ledina, Đurđica Cekinović Grbeša, Ivica Čabraja, Ivan-Christian Kurolt, Stela Halichidis, Victoria Birlutiu, Irina M Dumitru, Ruxandra Moroti, Aleksandra Barac, Goran Stevanovic, Athina Pyrpasopoulou, Vasilios Koulouras, Ljiljana Betica Radić, Metaxia N Papanikolaou, Emmanuel Roilides, Alemka Markotić, Ushma Galal, Emmanuelle Denis, Lynsey Goodwin, Lance Turtle, Simin Aysel Florescu, Hamdi Ramadani, Herman Goossens, Margareta Ieven, Christian Drosten, Peter W Horby, Reina S Sikkema, Marion P G Koopmans, PREPARE MERMAIDS ARBO investigator group, Louella M R Kasbergen, Erwin De Bruin, Felicity Chandler, Louise Sigfrid, Xin-Hui S Chan, Lauren Hookham, Jia Wei, Siyu Chen, Corine H GeurtsvanKessel, Sandra Scherbeijn, Remi N Charrel, Nazlı Ayhan, James L Lee, Victor M Corman, Chantal Reusken, Katherine Loens, Corneliu Petru Popescu, Mihaela Lupse, Violeta Briciu, Anca Meda Vasiesiu, Pellumb Pipero, Arjan Harxhi, Edmond Puca, Albina Ponosheci Biçaku, Maja Travar, Maja Ostojić, Rusmir Baljic, Jurica Arapović, Dragan Ledina, Đurđica Cekinović Grbeša, Ivica Čabraja, Ivan-Christian Kurolt, Stela Halichidis, Victoria Birlutiu, Irina M Dumitru, Ruxandra Moroti, Aleksandra Barac, Goran Stevanovic, Athina Pyrpasopoulou, Vasilios Koulouras, Ljiljana Betica Radić, Metaxia N Papanikolaou, Ioannis Andrianopoulos, Catalin Apostolescu, Silvia Bino, Maria Chondrogiorgi, Natalie Cleton, Daniel Codreanu, Tomasović Domagoj, Edita Dražić Maras, Mario Duvnjak, Adriana Hristea, Raluca M Hrisca, Kevin Jacobs, Ilias Iosifidis, Puškarić Ivana, Alma Gabriela Kosa, Iris Koshovari, Mandy Kuijstermans, Arsim Kurti, Santini Marija, Iosif Marincu, Julia Melchert, Pieter Moons, Visnja Mrdjen, Cristian M Niculae, Nenad Pandak, Lul Raka, Iordanis Romiopoulos, Željana Sulaver, Gratiela Tardei, Nijaz Tihic, Skuhala Tomislava, Antonija Verhaz, Mihaela Zaharia, Mačak Šafranko Željka, Ivana Vrkic, Ankica Vujovic, Emmanuel Roilides, Alemka Markotić, Ushma Galal, Emmanuelle Denis, Lynsey Goodwin, Lance Turtle, Simin Aysel Florescu, Hamdi Ramadani, Herman Goossens, Margareta Ieven, Christian Drosten, Peter W Horby, Reina S Sikkema, Marion P G Koopmans
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?